Arkansas Suspends Enforcement of Specialty Drug Distribution Law Following Constitutional Challenge

Key Takeaways

• The Arkansas State Board of Pharmacy has suspended enforcement of Act 630 of 2025 after a federal court concluded the law is likely unconstitutional under the dormant Commerce Clause.²
• The dispute highlights growing legal tension between state efforts to expand access to specialty medications and manufacturers' use of limited distribution networks to manage complex therapies.¹,³
• The litigation could influence future state regulation of specialty drug distribution and clarify constitutional limits on state oversight of pharmaceutical supply chains.¹

The Arkansas State Board of Pharmacy has voted to suspend enforcement of Act 630 of 2025, a law designed to limit pharmaceutical manufacturers' ability to maintain restricted or limited distribution networks for certain prescription drugs. The decision follows a federal court's preliminary injunction barring enforcement of the law against Novartis Pharmaceuticals after finding the statute is likely unconstitutional.¹,²

The Board's action marks a significant development in an ongoing legal dispute over the extent to which states may regulate specialty drug distribution systems and manufacturers' control over how certain high-risk or complex therapies reach patients.

Act 630 Sought to Expand Access to Limited Distribution Drugs

Enacted in 2025, Act 630 sought to increase access for Arkansas pharmacies to medications distributed through limited distribution networks. The law generally prohibited pharmaceutical manufacturers from restricting prescription medications to networks composed primarily of out-of-state pharmacies for more than three months after a product launch unless they obtained approval from the Arkansas State Board of Pharmacy. Manufacturers that failed to comply could face civil penalties and potential exclusion of their products from certain state health benefit programs.³

The Arkansas General Assembly stated that the legislation was intended to improve patient access to specialty medications, increase transparency surrounding limited distribution practices, and strengthen the role of in-state pharmacies in caring for Arkansas patients.³

Limited distribution networks are commonly used for specialty medications that require specialized storage, handling, patient education, or clinical monitoring. Manufacturers have argued that these networks help ensure product integrity and support safe use of therapies with complex administration or monitoring requirements.

Federal Court Finds Law Likely Violates the Dormant Commerce Clause

In Novartis Pharmaceuticals Corp. v. Griffin, the U.S. District Court for the Eastern District of Arkansas granted a preliminary injunction preventing enforcement of Act 630 against Novartis while the litigation proceeds. The court concluded that the manufacturer had demonstrated a likelihood of success on its claim that the statute violates the dormant Commerce Clause because it "overtly discriminates against interstate commerce in favor of in-state commerce."¹

The court also considered arguments that the law may conflict with federal regulation of drug distribution, including certain Food and Drug Administration requirements applicable to specialty therapies, although the preliminary injunction principally rested on the constitutional analysis.¹

The decision has broader implications because several other manufacturers and specialty pharmacy organizations have filed similar challenges to Act 630.²

Arkansas Board Suspends Enforcement Statewide

Following the preliminary injunction, the Arkansas Attorney General's Office advised the Arkansas State Board of Pharmacy that Act 630 was likely unconstitutional and unlikely to withstand further litigation. Based on that advice, the Board voted to suspend enforcement of the statute and to refrain from processing applications submitted under the law while litigation continues.²

Although enforcement has been suspended, Act 630 remains part of Arkansas law unless it is repealed by the legislature or ultimately invalidated by the courts. Lawmakers have indicated that future legislative revisions may be considered in response to the court's ruling.²

Implications for Manufacturers and Specialty Pharmacies

The dispute illustrates the increasingly complex legal environment surrounding specialty drug distribution.

For manufacturers, limited distribution networks often serve multiple purposes, including:

• Supporting compliance with specialized handling and storage requirements;
• Facilitating patient education and adherence programs;
• Monitoring adverse events and product safety;
• Coordinating distribution for therapies requiring specialized clinical oversight.

State efforts to expand access to those products through broader pharmacy participation may advance patient access goals but can also raise constitutional and operational questions when they affect interstate distribution systems.¹,³

For specialty pharmacies and health systems, the litigation underscores continuing uncertainty regarding state authority to regulate manufacturer distribution decisions. Organizations operating in multiple states should closely monitor similar legislative proposals, as several states have considered measures addressing specialty pharmacy access and limited distribution networks.

Broader Regulatory Implications

The Arkansas litigation reflects a broader trend of increased state involvement in pharmaceutical supply chain regulation. In recent years, states have pursued legislation addressing pharmacy benefit managers, drug pricing transparency, and manufacturer distribution practices.

The outcome of the Arkansas cases may influence future efforts to regulate specialty drug distribution and provide additional guidance regarding the constitutional limits on state regulation of interstate pharmaceutical commerce.¹

For pharmaceutical manufacturers, specialty pharmacies, and compliance professionals, the litigation reinforces the importance of evaluating state distribution requirements alongside federal regulatory obligations and constitutional considerations.

References

1. Novartis Pharmaceuticals Corp. v. Griffin. Order Granting Preliminary Injunction. US District Court for the Eastern District of Arkansas. Decided May 17, 2026. Accessed August 5, 2026. https://caselaw.findlaw.com/court/us-dis-crt-e-d-ark-cen-div/37209.html
2. Vrbin T. Arkansas suspends enforcement of law preventing limits on which pharmacies can sell medications. Arkansas Advocate. Published July 29, 2026. Accessed August 5, 2026. https://arkansasadvocate.com/2026/07/29/arkansas-suspends-enforcement-of-law-preventing-limits-on-which-pharmacies-can-sell-medications/
3. Arkansas General Assembly. Act 630 of 2025 (House Bill 1531). Enacted April 16, 2025. Accessed August 5, 2026. https://arkleg.state.ar.us/Home/FTPDocument?path=%2FACTS%2F2025R%2FPublic%2FACT630.pdf